The biotech industry is sounding the alarm as Trump’s tariffs put rare disease cell and gene therapy at risk. With over 10,000 rare diseases still lacking FDA-approved therapies, companies like BioMarin are urging the preservation of incentives to sustain innovation. BioMarin, known for gene therapies like Roctavian for hemophilia A, is facing financial challenges despite […]